secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001641172-25-013048
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones
--------------------------------------------------------------------------------

- Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
- Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.
- Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/0001641172-25-013048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000164117225013048/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer